FindTrial
Sign In

The consequences of mepolizumab-mediated depletion of eosinophils on adaptive and innate immune responses.

The consequences of mepolizumab-mediated depletion of eosinophils on adaptive and innate immune responses. - MEPO-AIR

Status
Unknown
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON45798
Enrollment
100
Registered
2017-10-13
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

adaptive and innate defense immune system

Interventions

None listed

Sponsors

Academisch Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: severe asthma

Exclusion criteria

Exclusion criteria: anemia, very low white blood cell count, anti-inflammatory and/or immunosuppressive medication other than used to treat asthma

Design outcomes

Primary

MeasureTime frame
genotyping white blood cells humoral parameters and cellular differentiation of mucosal tissue (sputum and nasal lavage)—

Secondary

MeasureTime frame
n.a.—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)